The American Journal of Medicine
Volume 123, Issue 4 , Pages 358-366.e2, April 2010

Systematic Review of the Symptom Burden, Quality of Life Impairment and Costs Associated with Peptic Ulcer Disease

  • Alan Barkun, MD, PhD

      Affiliations

    • Division of Gastroenterology, McGill University, Montreal, Quebec, Canada
    • Corresponding Author InformationRequests for reprints should be addressed to Alan Barkun, MD, PhD, Division of Gastroenterology, McGill University, 1650 Cedar Avenue, Montreal, Quebec H3G 1A4, Canada
  • ,
  • Grigorios Leontiadis, MD, PhD

      Affiliations

    • Division of Gastroenterology, McMaster University, Hamilton, Ontario, Canada

Abstract 

Background

Management of peptic ulcer disease has improved over the past few decades. However, the widespread use of nonsteroidal anti-inflammatory drugs and low-dose acetylsalicylic acid means that the burden of peptic ulcer disease remains a relevant issue.

Methods

We systematically searched PubMed and EMBASE for articles published 1966-2007 that reported symptoms, impairment of well-being or health-related quality of life, and costs associated with peptic ulcer disease.

Results

Thirty studies reported the prevalence of patient-reported gastrointestinal symptoms in individuals with endoscopically diagnosed symptomatic peptic ulcer disease. Average prevalence estimates, weighted by sample size, were 81% (95% confidence interval [CI], 77%-85%) for abdominal pain (11 studies), 81% (95% CI, 76%-85%) for pain specifically of epigastric origin (14 studies), and 46% (95% CI, 42%-50%) for heartburn or acid regurgitation (11 studies). On average, 29% (95% CI, 25%-34%) of patients with peptic ulcer disease presented with bleeding, often as the initial symptom (11 studies). Patients with peptic ulcer disease had significantly lower health-related quality of life than the general population, as measured by the Psychological General Well-Being index (P <.05; 7 studies) and the Short-Form-36 questionnaire (P <.05; 2 studies). Direct medical costs of peptic ulcer disease based on national estimates from several countries were USD163-866 per patient. The most costly aspects of peptic ulcer disease management were hospitalization and medication. Complicated peptic ulcer disease is particularly costly, estimated to be USD1883-25,444 per patient.

Conclusion

Peptic ulcer disease significantly impairs well-being and aspects of health-related quality of life, and is associated with high costs for employers and health care systems.

Keywords: Costs, Peptic ulcer disease, Quality of life, Symptom burden

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Funding: Writing support was provided by Dr. Catherine Henderson (Research Evaluation Unit, Oxford PharmaGenesis Ltd, Oxford, UK), funded by AstraZeneca R&D Mölndal, Sweden.

 Conflict of Interest: Dr. Alan Barkun is a consultant for AstraZeneca Inc. Dr. Grigorios Leontiadis has received speaker honoraria from AstraZeneca, Sanofi-Aventis, GlaxoSmithKline, and Janssen-Cilag.

 Authorship: This work is original, and the authors meet the criteria for authorship and accept responsibility for the scientific content of the manuscript.

PII: S0002-9343(09)01068-7

doi:10.1016/j.amjmed.2009.09.031

The American Journal of Medicine
Volume 123, Issue 4 , Pages 358-366.e2, April 2010